文献速递头颈部肿瘤放疗

诱导化疗与放疗间隔延长与鼻咽癌患者不良预后相关

The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma.
PubMed 文献 · Radiat Oncol · 2019-01-17

该研究基于2009至2012年住院数据库中新诊断非转移性鼻咽癌患者,比较诱导化疗与放疗间隔≤30天与>30天者的生存结局。共668例纳入,中位随访64.4个月;间隔>30天者5年总生存、无病生存和远处无转移生存均低于≤30天者,多因素分析显示间隔延长是总生存、无病生存和远处无转移生存的危险因素。

要点

  • 共668例鼻咽癌患者,608例间隔≤30天,60例间隔>30天,中位随访64.4个月。
  • 间隔>30天者5年总生存69.2%,≤30天者为86.6%。
  • 间隔延长是总生存(HR 2.44)、无病生存(HR 1.99)和远处无转移生存(HR 2.62)的危险因素。

核心结论

  • 诱导化疗与放疗间隔>30天与鼻咽癌患者远处转移和死亡风险显著升高相关。
  • 作者认为应努力避免诱导化疗与放疗之间的间隔延长,以降低治疗失败风险。

研究设计与样本

  • 从住院数据库筛选2009年至2012年新诊断、非转移性、接受诱导化疗后放疗的鼻咽癌患者。
  • 共668例符合纳入标准,按诱导化疗与放疗间隔分为≤30天组(608例)和>30天组(60例)。
  • 采用Kaplan-Meier法和log-rank检验比较生存,Cox模型进行多因素分析。

主要发现

  • 中位随访64.4个月。
  • 5年总生存率:间隔≤30天组86.6% vs 间隔>30天组69.2%。
  • 5年无病生存率:间隔≤30天组78.2% vs 间隔>30天组64.5%。
  • 5年远处无转移生存率:间隔≤30天组88.0% vs 间隔>30天组71.2%。
  • 5年局部区域无复发生存率:间隔≤30天组89.8% vs 间隔>30天组85.1%。

关键数值与推荐

  • 原文未报告指南或共识推荐条款。

临床怎么用

  • 作者结论认为应努力避免诱导化疗与放疗间隔延长,以降低治疗失败风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Induction chemotherapy (IC) now is gaining recognition for the treatment of nasopharyngeal carcinoma (NPC). The current study was conducted to examine the association between prognosis and the interval between IC and radiotherapy (RT) in NPC patients. METHODS: Patients with newly diagnosed, non-metastatic NPC who were treated with IC followed by RT from 2009 to 2012 were identified from an inpatient database. Overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS) and locoregional recurrence-free survival (LRFS) were compared between those with interval ≤ 30 and > 30 days by Kaplan-Meier and log-rank analyses; Cox modeling was used for multivariable analysis. RESULTS: A total of 668 patients met inclusion criteria with median follow-up of 64.4 months. Patients were categorized by interval: 608 patients with interval ≤ 30 days, and 60 with interval > 30 days. The 5-year OS, DFS, DMFS and LRFS rates were 86.6, 78.2, 88.0 and 89.8% for patients with interval ≤ 30 days, respectively, and 69.2, 64.5, 71.2 and 85.1% for patients with interval > 30 days, respectively. The prolonged interval was a risk factor for OS, DFS and DMFS with adjusted hazard ratios (95% confidence intervals) were 2.44 (1.48-4.01), 1.99 (1.27-3.11) and 2.62 (1.54-4.47), respectively. CONCLUSIONS: Prolonged interval > 30 days was associated with a significantly higher risk of distant metastasis and death in NPC patients. Efforts should be made to avoid prolonged interval between IC and RT to minimize the risk of treatment failure.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Peng L, Liu JQ, Xu C, et al. The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma. Radiat Oncol. 2019. PMID: 30654815. doi:10.1186/s13014-019-1213-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。